Gail Roboz

29PUBLICATIONS
183CO-AUTHORS
Gene and molecular therapyPredictive and prognostic markersMedical mycologyMedical molecular engineering of nucleic acids and proteinsMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Jun 02, 2026
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

|Feb 24, 2026
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos

|Dec 15, 2025
2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.

Jacqueline Cloos, Peter J M Valk, Christian Thiede

|Nov 21, 2025
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos

|Sep 25, 2025
Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.

Eunice S Wang, Pau Montesinos, James Foran

|Jul 16, 2025
Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome.

Jorge E Cortes, Jay Yang, Gail J Roboz

Pageof 5

Frequent Collaborators

10 joint publications

Andrew H Wei

5 joint publications

David Sallman

5 joint publications

Pau Montesinos

5 joint publications

Naval G Daver